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Radiotherapy outcome could be inﬂuenced by antioxidant capacity in breast cancer cell lines
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Introduction. The cancer cell radioresistance remains a fundamental barrier to attaining the maximal efﬁcacy of radiotherapy for
the treatment of breast cancer. Ionizing radiation (IR) enhances free radicals generation altering the redox status. The antioxidant
effect carried out by glutathione peroxidase (GPX) enzyme and glutathione (GSH) plays an important role reducing the harmful
action of the IR-induced reactive oxygen species (ROS).
Hypothesis. The downregulation of GPX and GSH through chemical inhibition using buthionine sulfoximine (BSO) could modify
the radiation response in different cell lines
Materials and methods. We used two cell lines of breast cancer (MDA-MB-231 and MCF-7) with different radiosensibility and
GSH/GSH+GSSG ratio (total GSH). MDA-MB-231 cell line was more radioresistant and showed higher levels of total GSH than
MCF-7 after IR. Pretreated cells with 100mM of BSO were irradiated al 2Gy. They were stopped at different times: short times
(0–210min) and long times (24–72h). We determined: (1) native antioxidant levels (reduced glutathione “GSH” and oxidized
“GSSG”) and (2) enzyme antioxidant activity (glutathione peroxidase “GPX”). The experiments were performed in triplicate for
each cell line.
Results. Measurements of GSH and GSSG showed an oscillatory pattern in both cell lines for short times (15–210min). Taking
into account long times (24–72h), GSH maximum values were obtained at 48h in MCF-7 and at 72h for MDA-MB-231 (P=0.0031
and P=0.0020, respectively). Concerning GSSG levels no differences were found in these cell lines. MDA-MB-231 showed an
upward trend for long times (24–72h) in GSH/GSH+GSSG ratio, reaching the maximum value after 72h (P<0.0001). Although
GSH/GSH+GSSG ratio did not reﬂect any differences in MCF-7, it was higher than in MDA-MB-231 cell line. Interestingly, this
pattern was inverted when the cell lines were treated without BSO. Our results showed two maximum values (15min and 72h,
P<0.0001) for GPX activity levels in MDA-MB-231. We also found maximum values (90 and 150min and 72h; P<0.0001) for GPX
activity levels in MCF-7.
Conclusions. The antioxidant capacity could inﬂuences the radiation treatment in the breast cancer cell lines used in this work.
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Objective. IMRT use for breast cancer remains controversial. In complex situations, 3DCRT does not allow coverage of PTV with
sparing of healthy tissues.Wepresent thedosimetric results of ﬁrst patients treated at our institutionusing volumetricmodulated
arctherapy (VMAT).
Materials and methods. Nine patients with complex anatomy, were selected for treatment with RapidArc. Two partial arcs (240◦)
delivered 6MV photons. The prescribed dose to breast and lymph nodes was 52.2Gy with an integrated boost to the tumor bed
at 63.2Gy in 29 fractions. PTV was created by extension of 7mm from CTV with the exclusion of the ﬁrst 5mm under the skin.
Dosimetric results concerning the PTV coverage and normal tissues sparing were collected.
Results. 95% of the breast PTV received 91.7% of the prescribed dose [80.6–98.2]. 95% of the supraclavicular PTV received 88.5% of
the prescribed dose [72–98]. 95% of the MIC PTV received 90% of the prescribed dose [75–100]. The ipsilateral lung V5, V20 and
V30 were 90% [75–100], 23.6% [13.7–35] and 9.7% [4.7–14], respectively. The average dose was 15 Gy [11–19]. The contralateral lung
V5 and V10 were 38.9% [16.6–68.5] and 5.4% [0–15], respectively. The average dose was 5Gy [3.4–7.2]. The heart V5 and V35 were
78.1% [49–100] and 0.8% [0–5]. The average dose was 14Gy [9–19]. The contralateral breast V5 and V10 were 23.6% [0.8–64.9] and
4.4% [0–20]. The average dose was 4.1Gy [2.1–7.3]. The average delivered monitor unit was 568UM [448–772].
Conclusion. RapidArc treatment yielded satisfactory PTV coverage while sparing healthy tissues where conventional radiotherapy
would not have been acceptable.
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